Evaluation and Comparison of Practice Guidelines and Consensus on Type 2 Diabetes:A Systematic Appraisal
GU Xin-chun1,2, WANG Tian-sheng2, DONG Shu-jie1, ZHAI Suo-di1*
1. Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China; 2. Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Science, Peking University, Beijing 100191, China
Abstract��OBJECTIVE To evaluate the quality of now available clinical guidelines and consensus statements on type 2 diabetes. Based on this assessment, the comparison of guidelines and consensuses is made to give some suggestions on the METHODS of making these documents. METHODS PubMed, Embase, CNKI, Wanfang, SinoMed and guideline websites were systematically searched. Literatures were screened according to defined criteria for including. AGREE �� was used to instrument assess the quality of the guidelines and consensuses. RESULTS The result showed that the quality of included guidelines is various, but the overall quality of guidelines is still higher than consensuses. Guidelines got high scores in scope and purpose domain and clarity of presentation domain, but low scores in rigor of development domain and applicability domain. Consensus statements got low scores in all 6 domains. CONCLUSION The main reason for the difference is consensuses have poor methodology. Rapid advice guidelines were suggested as an alternative for consensus statements.
��짴�, ������, �����, ������. ����AGREE ���2������ָ�Ϻ�ʶ��������[J]. �й�ҩѧ��־, 2016, 51(18): 1626-1630.
GU Xin-chun, WANG Tian-sheng, DONG Shu-jie, ZHAI Suo-di. Evaluation and Comparison of Practice Guidelines and Consensus on Type 2 Diabetes:A Systematic Appraisal. Chinese Pharmaceutical Journal, 2016, 51(18): 1626-1630.
SUN Z X, LIU N F. The guiding role of clinical practice guidelines in good evidence-based clinical pharmacy practice [J]. Chin Pharm J(�й�ҩѧ��־),2014,49(21):1950-1956.
[2]
AGREE COLLABORATION. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines:the AGREE project, Qual. Saf[J]. Health Care,2003,12(1):18-23.
[3]
AMERICAN DIABETES ASSOCIATION. Standards of medical care in diabetes 2015[J]. Diabetes Care,2015,38(suppl):4.
[4]
HANDELSMAN Y, BLOOMGARDEN Z T, GRUNBERGER G, et al. American association of clinical endocrinologists and american college of endocrinology-clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015[J]. Endocr Pract, 2015,21(suppl 1):187.
[5]
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCEL-LENCE. Type 2 diabetes:The management of type 2 diabetes[EB/OL]. London (UK):National Institute for Health and Clinical Excellence,2009(Updated in 2014),[2015-11-02]. https://www.nice.org.uk/guidance/cg87
[6]
INTERNATIONAL DIABETES FEDERATION GUIDELINE DEVELOPMENT GROUP.Global guideline for type 2 diabetes[J]. Diabetes Res Clin Pract, 2014,104(1):152.
[7]
INTERNATIONAL DIABETES FEDERATION GUIDELINE DEVELOPMENT GROUP. Guideline for management of postmeal glucose in diabetes[J]. Diabetes Res Clin Pract, 2014, 103(2):256-268.
[8]
GOH S Y, ANG S B, BEE Y M, et al. Ministry of health clinical practice guidelines:diabetes mellitus[J]. Singapore Med J, 2014,55(6):334-347.
[9]
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCEL-LENCE.Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes [EB/OL]. London (UK):National Institute for Health and Clinical Excellence,2012(Updated in 2014), [2015-11-02]. https://www.nice.org.uk/guidance/ta248.
[10]
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCEL-LENCE. Dapagliflozin in combination therapy for treating type 2 diabetes[EB/OL]. London (UK):National Institute for Health and Clinical Excellence,2013[2015-11-02]. https://www.nice.org.uk/guidance/ta288.
[11]
UNVIVERSITY OF MICHIGAN HEALTH SYSTEM. Management of Diabetes Mellitus [EB/OL]. Michigan(USA):Unviversity of Michigan Health System,2014[2015-11-02].http://www.med.umich.edu/index.html
[12]
INSTITUTE FOR CLINICAL SYSTEMS IMPROVEMENT. Diagnosis and Management of Type 2 Diabetes Mellitus in Adults [EB/OL]. Bloomington (MN):Institute for Clinical Systems Improvement,2014[2015-11-02]. http://www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_endocrine_guidelines/diabetes/
[13]
PETER J G, STEFAN D A, CHRISTIAN B,et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD[J]. Eur Heart J, 2013,34(39):3035-3087.
[14]
COPELAND K C, SILVERSTEIN J, MOORE K R, et al. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents [J]. Pediatrics, 2013, 131(2):364-382.
[15]
CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH. Optimal Use Recommendations for Second-and Third-Line Therapy for Patients With Type 2 Diabetes [EB/OL]. Ottawa (ON). Canadian Agency for Drugs and Technologies in Health,2013[2015-11-02]. https://www.cadth.ca/second-third-line-therapies-type-2-diabetes
[16]
CHINESE DIABETES SOCIETY.Chinese type 2 diabetes prevention and therapy guideline [J].Chin J Diabetes(�й�������־),2014,8:242.
[17]
QASEEM A, HUMPHREY L L, SWEET D E, et al. Oral pharmacologic treatment of type 2 diabetes mellitus:a clinical practice guideline from the American College of Physicians [J]. Ann Intern Med, 2012,156(3):218-231.
[18]
KO S H, KIM S R, KIM D J, et al. 2011 Clinical practice guidelines for type 2 diabetes in Korea [J]. Diabetes Metab J, 2011,35(5):431-436.
THE DEPARTMENT OF VETERANS AFFAIRS AND THE DEPARTMENT OF DEFENSE.(2010) VA/DoD clinical practice guideline for the management of diabetes mellitus[EB/OL]. NW Washington DC (USA):The Department of Veterans Affairs and The Department of Defense, 2010[2015-11-02]. http://www.healthquality.va.gov/guidelines/CD/diabetes/
[21]
GARBER A J, ABRAHAMSON M J, BARZILAY J I, et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement[J]. Endocr Pract,2013,19(3):536-557.
[22]
KIRKMAN M S, BRISCOE V J, CLARK N, et al. Diabetes in older adults:a consensus report [J]. J Am Geriatr Soc,2012,60(12):2342-2356.
[23]
MENENDEZ T E, LAFITA T J, ARTOLA M S, et al. Recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes[J]. Consensus Document Nefrologia,2011,31(1):17-26.
[24]
WOO J T, PARK K S, BYUN D W, et al. Regulation of glucose control in people with type 2 diabetes:a review and consensus[J]. Korean Diabetes J,2010,34(1):16-20.
[25]
GUZMAN J R, LYRA R, AGUILAR-SALINAS C A, et al. Treatment of type 2 diabetes in Latin America:a consensus statement by the medical associations of 17 Latin American countries. Latin American Diabetes Association[J]. Rev Panam Salud Publica,2010,28(6):463-471.
[26]
RAMSAY S, WALKER J D, JAPP A. Achieving consensus on current diabetes issues[J]. Br J Diabe Vascul Dis,2010,10(4):157-160.
[27]
CHINESE DIABETES SOCIETY. Clinical practice consensus on GLP-1 receptor agonist drugs [J]. Chin J Diabetes(�й�������־),2014,6(1):1420.
[28]
CHINESE SOCIETY OF ENDOCRINOLOGY. Chinese consensus on insulin use in type 2 diabetes in adults[J]. Chin J Endocrinol Metab(�л��ڷ��ڴ�л��־),2013,29(1):16.
[29]
CHINA ASSOCIATION OF GERONTOLOGY AND GERIATRICS. Consensus on diagnosis and therapy of diabetes in old people [J]. Chin J Intern Med(�л��ڿ���־), 2014, 53(3):243-251.
[30]
CHINESE DIABETES SOCIETY. Consensus on insulin short term therapy of newly diagnosed type 2 diabetes [J]. Natl Med J China(�л�ҽѧ��־), 2013,93(20):1524-1526.
[31]
CHINESE SOCIETY OF ENDOCRINOLOGY. Chinese consensus on the use of insulin secretagogue in adult type 2 diabetes [J]. Chin J Endocrinol Metab(�л��ڷ��ڴ�л��־),2012,28(4):261-265.
[32]
CHINESE PEDIATRIC SOCIETY. Guidelines on insulin therapy in children and adolescent [J]. Chin J Pediatr(�л�������־), 2010,48(6):431-435.
2016, Vol. 51 
